Literature DB >> 19187116

Expressions of p53, cyclinD1 and histopathological features in basal cell carcinomas.

Resit D Koseoglu1, Engin Sezer, Ahmet Eyibilen, Ibrahim Aladag, Ilker Etikan.   

Abstract

BACKGROUND: We planned this study to analyze probable associations between p53, cyclinD1, Ki67 and histopathological features in basal cell carcinomas (BCC).
METHODS: Histological differentiation types, histological growth patterns and tissue responses were analyzed in 50 cases of BCC. In immunohistochemical analysis, p53, cyclinD1 and Ki67 antibodies were investigated. P53 expression was evaluated based on a cut-off value of 25% positivity. CyclinD1 expression was graded from 0 to 3+ according to the percentage of positive nuclear staining. The percentage of positively staining cells for Ki67 was recorded.
RESULTS: The following significant correlations were detected. Solid infiltrative type differentiation was related to the infiltrative histological growth pattern. The rates of p53 positivity and severe fibrosis in the groups of mixed and infiltrative growth patterns were higher than others. Besides, p53-positive cases showed more severe fibrosis and had a higher mean value for Ki67 index. Epidermal p53 and cyclinD1 clones in normal epidermal areas adjacent to tumors were noticed in 42% and 52% of the cases, respectively.
CONCLUSIONS: P53 expression seems to be related to Ki67 index and some histopathological features of BCC, such as infiltrative histological growth pattern and probably fibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19187116     DOI: 10.1111/j.1600-0560.2008.01204.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  7 in total

1.  Polysaccharides from Capsosiphon fulvescens stimulate the growth of IEC-6 Cells by activating the MAPK signaling pathway.

Authors:  Hiroe Go; Hye-Jung Hwang; Taek-Jeong Nam
Journal:  Mar Biotechnol (NY)       Date:  2010-08-10       Impact factor: 3.619

2.  TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features.

Authors:  António Castanheira; Maria João Vieira; Mafalda Pinto; Carolina Dias; Luísa Prada; Sofia Macedo; Margarida Sá Fernandes; Fortunato Vieira; Paula Soares; Alberto Mota; José Manuel Lopes; Paula Boaventura
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

3.  High-Risk BCC Of the Lower Eyelid in Patient with Presternal Located Cutaneous Melanoma and BCC Of the Shoulder: Melolabial Advancement Flap Combined with Undermining Surgical Approach As Promising Complex One Step Treatment Option!

Authors:  Georgi Tchernev; Ilia Lozev; Ivan Pidakev; Irina Yungareva; Tanya Naskova-Popova; Ivanka Temelkova
Journal:  Open Access Maced J Med Sci       Date:  2018-11-21

Review 4.  Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma.

Authors:  Toshihiko Hoashi; Naoko Kanda; Hidehisa Saeki
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

5.  Immunohistochemical evaluation of p53 and Ki67 expression in skin epithelial tumors.

Authors:  Effat Khodaeiani; Ashraf Fakhrjou; Mehdi Amirnia; Shahla Babaei-Nezhad; Farshid Taghvamanesh; Elham Razzagh-Karimi; Hossein Alikhah
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

6.  ClC-3 Chloride Channel Proteins Regulate the Cell Cycle by Up-regulating cyclin D1-CDK4/6 through Suppressing p21/p27 Expression in Nasopharyngeal Carcinoma Cells.

Authors:  Dong Ye; Hai Luo; Zhouyi Lai; Lili Zou; Linyan Zhu; Jianwen Mao; Tim Jacob; Wencai Ye; Liwei Wang; Lixin Chen
Journal:  Sci Rep       Date:  2016-07-25       Impact factor: 4.379

7.  Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway.

Authors:  Liying Zhu; Longguang Dai; Nenghong Yang; Mi Liu; Shuang Ma; Chengcheng Li; Jie Shen; Tao Lin; Dan Wang; Wei Pan; Xing Li
Journal:  Cell Biochem Funct       Date:  2020-03-09       Impact factor: 3.685

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.